



Neuland Q3FY25 Total income at Rs.401.9 crore; EBITDA at Rs.90.3 crore

Hyderabad, India, February 10, 2025 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the third quarter & nine months ended December 31st, 2024.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“We saw marginal topline growth this quarter as compared to Q3FY24. Nevertheless, these results align with our initial outlook at the start of the year regarding our expectations for FY25. We are steadily advancing our strategic initiatives and remain optimistic about achieving sustainable long-term growth through acquiring new customers, enhancing our expertise, expanding our capacity flexibly, and refining our processes.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *“This quarter’s revenues were driven by several important molecules in the commercial CMS and GDS segments. We expect the recently commercialized molecules to scale even as we are on track to enhance our manufacturing capacity. There is good traction from our existing customers reverting for multiple projects as well as fresh interest from a range of new customers. We are seeing increased interest in peptides leading to our recent decision to invest in a larger capacity. Overall, we are confident on the business momentum for the medium as well as long term.”*

Financial Summary

Particulars	Rs. crore							
	Q3FY25	Q3FY24	YoY Growth (%)	Q2FY25	QoQ Growth (%)	9MFY25	9MFY24	YoY Growth (%)
Total Income	401.9	394.9	1.8%	315.2	27.5%	1,161.5	1,180.8	-1.6%
EBITDA	90.3	122.7	-26.4%	65.7	37.5%	284.6	362.3	-21.5%
EBITDA margin (%)	22.5%	31.1%	-860 bps	20.8%	170 bps	24.5%	30.7%	-620 bps
Exceptional Item*	55.8	-	-	-	-	76.4	-	-
PAT*	101.4	80.7	25.6%	32.0	217.3%	231.7	232.0	-0.1%
PAT margin (%)	25.2%	20.4%	480 bps	10.1%	1510 bps	19.9%	19.6%	30 bps
EPS (Basic) Rs.	79.0	62.9	25.6%	24.9	217.3%	180.6	180.8	-0.1%



*Q3FY25 and 9MFY25 Includes exceptional item of sale of investment property of Rs. 55.8 crores and Rs. 76.4 crores respectively.

Q3 FY25 Earnings Call

The company will conduct a one-hour Earnings call at **16:00 hrs. IST on Tuesday, February 11, 2025** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed over 980+ Regulatory filings in the US (70 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com